These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 27476707)

  • 41. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
    Tsai YW; Wen YW; Huang WF; Chen PF; Kuo KN; Hsiao FY
    J Gastroenterol; 2011 Jan; 46(1):39-45. PubMed ID: 20811753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is there a dark side to long-term proton pump inhibitor therapy?
    Nealis TB; Howden CW
    Am J Ther; 2008; 15(6):536-42. PubMed ID: 19127138
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 25 Years of Proton Pump Inhibitors: A Comprehensive Review.
    Strand DS; Kim D; Peura DA
    Gut Liver; 2017 Jan; 11(1):27-37. PubMed ID: 27840364
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evidence-based clinical practice guidelines for peptic ulcer disease 2015.
    Satoh K; Yoshino J; Akamatsu T; Itoh T; Kato M; Kamada T; Takagi A; Chiba T; Nomura S; Mizokami Y; Murakami K; Sakamoto C; Hiraishi H; Ichinose M; Uemura N; Goto H; Joh T; Miwa H; Sugano K; Shimosegawa T
    J Gastroenterol; 2016 Mar; 51(3):177-94. PubMed ID: 26879862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease.
    Tomita T; Fukuda Y; Tamura K; Tanaka J; Hida N; Kosaka T; Hori K; Sakagami T; Satomi M; Shimoyama T
    Aliment Pharmacol Ther; 2002 Apr; 16 Suppl 2():204-9. PubMed ID: 11966543
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Economic and health impacts of Helicobacter pylori eradication strategy for the treatment of peptic ulcer disease: A cost-effectiveness analysis.
    Kowada A; Asaka M
    Helicobacter; 2022 Jun; 27(3):e12886. PubMed ID: 35343031
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prophylaxis and treatment of non-steroidal anti-inflammatory drug-induced upper gastrointestinal side-effects.
    Lazzaroni M; Bianchi Porro G
    Dig Liver Dis; 2001 Dec; 33 Suppl 2():S44-58. PubMed ID: 11827362
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.
    Yu LY; Sun LN; Zhang XH; Li YQ; Yu L; Yuan ZQ; Meng L; Zhang HW; Wang YQ
    Adv Ther; 2017 May; 34(5):1070-1086. PubMed ID: 28429247
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Indications and consequences of Helicobacter pylori eradication on gastroesophageal reflux disease].
    Gisbert JP; Piqué JM
    Med Clin (Barc); 2005 May; 124(18):697-709. PubMed ID: 15899166
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis.
    Ren LH; Chen WX; Qian LJ; Li S; Gu M; Shi RH
    World J Gastroenterol; 2014 Mar; 20(9):2412-9. PubMed ID: 24605040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.
    Targownik LE; Fisher DA; Saini SD
    Gastroenterology; 2022 Apr; 162(4):1334-1342. PubMed ID: 35183361
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proton Pump Inhibitors: What the Internist Needs to Know.
    Spechler SJ
    Med Clin North Am; 2019 Jan; 103(1):1-14. PubMed ID: 30466666
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proton pump inhibitors: balancing the benefits and potential fracture risks.
    Richards JB; Goltzman D
    CMAJ; 2008 Aug; 179(4):306-7. PubMed ID: 18695170
    [No Abstract]   [Full Text] [Related]  

  • 54. Proton pump inhibitor use and the risk of fractures among an older adult cohort.
    Harding BN; Weiss NS; Walker RL; Larson EB; Dublin S
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):596-603. PubMed ID: 29493043
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of proton pump inhibitors after antireflux surgery: a nationwide register-based follow-up study.
    Lødrup A; Pottegård A; Hallas J; Bytzer P
    Gut; 2014 Oct; 63(10):1544-9. PubMed ID: 24474384
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.
    Ohara T; Morishita T; Suzuki H; Masaoka T; Ishii H
    Hepatogastroenterology; 2004; 51(56):338-42. PubMed ID: 15086153
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Bleeding ulcers: prevention of relapse: continuous PPI use no better than intermittent].
    Escher M
    Dtsch Med Wochenschr; 2015 Jan; 140(1):14. PubMed ID: 25580963
    [No Abstract]   [Full Text] [Related]  

  • 58. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
    Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
    Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of clinical pharmacists' recommendations on a proton pump inhibitor taper protocol in an ambulatory care practice.
    Bundeff AW; Zaiken K
    J Manag Care Pharm; 2013 May; 19(4):325-33. PubMed ID: 23627578
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.